Developer and Security Teams No Longer Have to Make Tradeoffs Between the Autonomy, Capability and Security of Coding AgentsSAN FRANCISCO, March 19, 2026 (GLOBE NEWSWIRE) -- Keycard, the provider of ...
(NYSE: PFE) today announced positive topline results from the Phase 3 TALAPRO-3 study of TALZENNA ® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI ® ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results